Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced its upcoming participation in key investor conferences, aimed at showcasing its advancements and ongoing projects in the healthcare sector. The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:30 a.m. PT / 2:30 p.m. ET, followed by its engagement at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 9:30 a.m. PT / 12:30 p.m. ET. Investors and interested parties can access live webcasts of these events via the Tarsus website, where replays will also be available within 48 hours and archived for a limited duration.

Tarsus Pharmaceuticals is dedicated to leveraging proven scientific methods and innovative technologies to revolutionize patient treatment. The company focuses particularly on eye care and infectious disease prevention, addressing significant unmet medical needs across various therapeutic categories. Its flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, has already received FDA approval for treating Demodex blepharitis, marking a significant step in the company's commitment to eye care.

In addition to XDEMVY, Tarsus is advancing its pipeline with promising candidates currently in Phase 2 clinical trials, including TP-04, an ophthalmic gel aimed at treating ocular rosacea, and TP-05, an oral tablet for Lyme disease prevention. The ongoing developments reflect Tarsus's strategic focus on innovative treatments that have the potential to change the landscape of their respective fields.

For media inquiries, Adrienne Kemp, Senior Director of Corporate Communications, can be reached at (949) 922-0801, while investor relations inquiries can be directed to David Nakasone at (949) 620-3223.

As Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) gears up for participation in two prominent investor conferences—the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference—investors should closely monitor developments related to the company, especially regarding its innovations in eye care and infectious disease prevention.

Tarsus is capitalizing on a significant market opportunity by targeting diseases with high unmet medical needs, particularly in ophthalmology. With the FDA-approved XDEMVY® (lotilaner ophthalmic solution) now available for the treatment of Demodex blepharitis, Tarsus has established a foothold in the eye care sector. The ongoing development of TP-04 and TP-05 highlights the company's commitment to expanding its product pipeline. TP-04 aims for a novel treatment of ocular rosacea, while TP-05 seeks to provide a preventative solution for Lyme disease. Both candidates are currently in Phase 2 trials, and successful outcomes could further enhance Tarsus's valuation and market position.

Investors should consider the broader implications of Tarsus's participation in these conferences. They will provide management with a platform to outline their strategic vision and update stakeholders on clinical advancements and future milestones. Engaging with potential investors can generate interest and confidence in Tarsus's growth trajectory.

Given the current climate in the pharmaceutical sector, characterized by a heightened focus on innovative treatments and investor support for companies that demonstrate robust development pipelines, Tarsus could represent an attractive investment. Interested parties should keep a close watch on the conference proceedings for key insights, potential partnerships, and product updates that may influence stock performance in the near term. Investing in Tarsus at this pivotal moment could yield substantial returns as the company continues to advance its transformative therapies.